Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.74 |
| ▸ | CDK2 | P24941 | 10/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.59 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954267 | 0.85 | GSK3B (1.00) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL13146282 | 0.85 | GSK3B (0.73) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14543183 | 0.85 | GSK3B (0.67) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL12953281 | 0.84 | GSK3B (0.72) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13998502 | 0.83 | GSK3B (0.87) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13998461 | 0.83 | GSK3B (0.82) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13146723 | 0.83 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13118479 | 0.82 | GSK3B (1.00) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14613394 | 0.82 | GSK3B (0.69) | GSK3BCDK2CCNA2CCNA1CHEK1 | |
| SCHEMBL13893732 | 0.82 | GSK3B (0.83) | GSK3BCDK2CCNA2CCNA1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |